43 related articles for article (PubMed ID: 11484509)
1. DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases.
Mori T; Iwasaki T; Sonoda H; Kawaguchi K; Tomonaga T; Furukawa H; Sato C; Shiraishi S; Taguchi K; Tamiya S; Yoneda R; Oshiro Y; Matsunobu T; Abe C; Kuboyama Y; Ueki N; Kohashi K; Yamamoto H; Nakashima Y; Oda Y
Hum Pathol; 2024 Mar; 145():56-62. PubMed ID: 38401716
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
3. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
4. Primary hepatic pleomorphic liposarcoma: Case report and literature review.
Redrobán L; Lara-Endara J; Montalvo N; Armijos C; Rodríguez-Suárez J; Serpa F
Rev Esp Patol; 2024; 57(2):128-132. PubMed ID: 38599733
[TBL] [Abstract][Full Text] [Related]
5. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
Dei Tos AP; Doglioni C; Piccinin S; Maestro R; Mentzel T; Barbareschi M; Boiocchi M; Fletcher CD
J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
[TBL] [Abstract][Full Text] [Related]
6. Low-grade central osteosarcoma with extraosseous dedifferentiation: a rare case.
Kawaguchi K; Kohashi K; Sagiyama K; Hashisako M; Nabeshima A; Setsu N; Endo M; Iwasaki T; Nakashima Y; Oda Y
Skeletal Radiol; 2024 Mar; ():. PubMed ID: 38467824
[TBL] [Abstract][Full Text] [Related]
7. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator.
Okoro DR; Arva N; Gao C; Polotskaia A; Puente C; Rosso M; Bargonetti J
PLoS One; 2013; 8(10):e77643. PubMed ID: 24147044
[TBL] [Abstract][Full Text] [Related]
8. Predicting dedifferentiation in liposarcoma: a proteomic approach.
McClain CM; Friedman DB; Hajri T; Coffin CM; Cates JM
Virchows Arch; 2013 Jul; 463(1):85-92. PubMed ID: 23709017
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal well-differentiated inflammatory liposarcoma: a diagnostic dilemma.
Kawano R; Nishie A; Yoshimitsu K; Irie H; Tajima T; Hirakawa M; Ishigami K; Ushijima Y; Okamoto D; Yabuuchi H; Taketomi A; Nishihara Y; Fujita N; Honda H
Radiat Med; 2008 Aug; 26(7):450-3. PubMed ID: 18770006
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
Crago AM; Singer S
Curr Opin Oncol; 2011 Jul; 23(4):373-8. PubMed ID: 21552124
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
13. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
14. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
